Literature DB >> 22119833

E-cadherin in gastric carcinomas related to histological prognostic parameters.

Diana Stănculescu1, Cl Mărgăritescu, A Stepan, Anca Oana Mitruţ.   

Abstract

AIM: The immunohistochemical study of E-cadherin in gastric carcinomas, related to tumor aggressiveness factors (invasive and metastatic potential).
MATERIALS AND METHODS: The studied material was gastric resection specimens taken from of 60 patients with gastric cancer, during 2009. The tissue was processed using standard histopathological technique, which allowed the assessment of the well-known morphological parameters of prognostic value. Later on the specimens has undergone immunohistochemical processing for E-cadherin (NCH-38 clone), to evaluate its expression in relation with these prognostic parameters.
RESULTS: E-cadherin was positive in 65% from gastric carcinomas, with highest positivity index for well (80% cases) and moderate (17.64% cases) differentiated intestinal type tumors, while a large number of poorly differentiated tumors (55.55%) were E-cadherin negative. Among diffuse type carcinomas, the majority of advanced stage tumors (50% of serosal invasive tumors and 100% of peritoneal disseminated tumors) and also a high number of tumors with vascular and lymphatic invasion (50% and respective 80% cases) represented the E-cadherin negative category (54.54%). The E-cadherin staining was also negative in 75% of lymph node positive diffuse type carcinomas and in all metastatic tumors.
CONCLUSIONS: We found that irrespective of histologic type, the E-cadherin expression was reduced to negativity in advanced stages of gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22119833

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  10 in total

1.  Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma.

Authors:  H Dong; L Xie; C Tang; S Chen; Q Liu; Q Zhang; W Zheng; Z Zheng; H Zhang
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

Review 2.  Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications.

Authors:  Danilo do Rosário Pinheiro; Wallax Augusto Silva Ferreira; Mariceli Baia Leão Barros; Mariana Diniz Araújo; Symara Rodrigues-Antunes; Bárbara do Nascimento Borges
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

3.  Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review).

Authors:  Feng Jiao; Ziliang Jin; Lei Wang; Liwei Wang
Journal:  Biomed Rep       Date:  2013-08-20

4.  mRNA Expression Analysis of E-Cadherin, VEGF, and MMPs in Gastric Cancer: a Pilot Study.

Authors:  Puneet Kumar; Arun Sebastian; Khushi Verma; Ruhi Dixit; Soni Kumari; Juhi Singh; Satyendra Kumar Tiwary; Gopeshwar Narayan
Journal:  Indian J Surg Oncol       Date:  2020-05-22

5.  Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer.

Authors:  Raefa Abou Khouzam; Chiara Molinari; Samanta Salvi; Monica Marabelli; Valeria Molinaro; Donata Orioli; Luca Saragoni; Paolo Morgagni; Daniele Calistri; Guglielmina Nadia Ranzani
Journal:  Oncotarget       Date:  2017-03-21

Review 6.  Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review).

Authors:  Taxiarchis Konstantinos Nikolouzakis; Loukia Vassilopoulou; Persefoni Fragkiadaki; Theodoros Mariolis Sapsakos; Georgios Z Papadakis; Demetrios A Spandidos; Aristides M Tsatsakis; John Tsiaoussis
Journal:  Oncol Rep       Date:  2018-03-21       Impact factor: 4.136

Review 7.  Endocrine Disruptors Leading to Obesity and Related Diseases.

Authors:  Demetrios Petrakis; Loukia Vassilopoulou; Charalampos Mamoulakis; Christos Psycharakis; Aliki Anifantaki; Stavros Sifakis; Anca Oana Docea; John Tsiaoussis; Antonios Makrigiannakis; Aristides M Tsatsakis
Journal:  Int J Environ Res Public Health       Date:  2017-10-24       Impact factor: 3.390

8.  Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer.

Authors:  Shuhei Kushiyama; Masakazu Yashiro; Yurie Yamamoto; Tomohiro Sera; Atsushi Sugimoto; Sadaaki Nishimura; Shingo Togano; Kenji Kuroda; Mami Yoshii; Tatsuro Tamura; Takahiro Toyokawa; Hiroaki Tanaka; Kazuya Muguruma; Hiroshi Nakada; Masaichi Ohira
Journal:  Mol Clin Oncol       Date:  2021-03-19

9.  The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma.

Authors:  Hongmei Dong; Hong Guo; Liangxi Xie; Geng Wang; Xueyun Zhong; Thaer Khoury; Dongfeng Tan; Hao Zhang
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

10.  Lauren classification and individualized chemotherapy in gastric cancer.

Authors:  Junli Ma; Hong Shen; Linda Kapesa; Shan Zeng
Journal:  Oncol Lett       Date:  2016-03-16       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.